Creative Biolabs Ready to Accelerate Oncolytic Virotherapy Research on Melanoma/GU Cancers/GI Cancers

With the well-established OncoVirapy™ platform, Creative Biolabs announces the extension of disease-specific oncolytic virus therapy development services to cover melanoma, genitourinary cancers, gastrointestinal cancers, etc.

New York, USA – November 1, 2021 – The increasing incidence of cancers across the globe has significantly boosted the demand for efficient cancer therapies. Among various kinds of therapies under research, oncolytic virotherapy has emerged as a potential treatment approach to treat malignant tumors and is expected to become one of the primary therapies to treat cancer.

With an unrelenting drive in bio-scientific research and industry, Creative Biolabs has successfully developed the OncoVirapy™ platform to efficiently support oncolytic virus design, engineering, validation, and manufacture. Now, backed up by this powerful platform, the scientist team announces the extension of disease-specific oncolytic virus therapy development services to cover melanoma, genitourinary cancers, gastrointestinal cancers, etc.

Oncolytic Virotherapy for Melanoma

Creative Biolabs is now releasing a comprehensive suite of oncolytic virotherapy development services to support the oncolytic virus research in melanoma treatment. The experienced scientists can skillful manipulate the whole process: candidate virus species will be carefully selected and conferred with enhanced antitumor functions by genetic engineering, then in vitro and in vivo assays will be designed for therapeutic effect validation.

Oncolytic Virotherapy for Genitourinary Malignancies

On the basis of genetic mutations, viral tropisms, and arming viruses, Creative Biolabs can provide virus vector design and validation services for genitourinary (GU) malignancies. More techniques, such as combining oncolytic virus with gene therapy, coat modification of oncolytic virus, and administration of oncolytic virus using carrier cells, are available in addition to the aforementioned methods.

Oncolytic Virotherapy for Gastrointestinal Cancers

Oncolytic virotherapy is arising as an promising treatment strategy as several studies have shown that oncolytic virus shows anti-tumor efficacy in gastrointestinal(GI) cancers. The expert at Creative Biolabs considers oncolytic virotherapy a promising method especially for gastric cancer and pancreatic cancer for its tumor selectivity and cancer-killing ability, and is dedicated to designing novel therapeutic strategies with fully-custom solutions.

“With the experienced team consisting of scientists of Ph. D level and dedicated managers, we will continue to provide high-quality oncolytic virus products and develop more efficient oncolytic virotherapy strategies to make a further contribution to related research of global scientists,” as introduced by a senior scientist at Creative Biolabs.

For those interested in learning more, please visit the official website

About Creative Biolabs

Empowered by leading technology and years of experience in biomedical science, Creative Biolabs is dedicated to offering comprehensive, end-to-end oncolytic virus therapy development services. The whole pipeline covers oncolytic virus engineering, in vitro validation study, in vivo preclinical study, disease-specific oncolytic virotherapy development, etc.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States